---
title: "Xtant Med | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 20.88 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286248416.md"
datetime: "2026-05-13T11:07:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286248416.md)
  - [en](https://longbridge.com/en/news/286248416.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286248416.md)
---

# Xtant Med | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 20.88 M

Revenue: As of FY2026 Q1, the actual value is USD 20.88 M, beating the estimate of USD 19.79 M.

EPS: As of FY2026 Q1, the actual value is USD -0.02.

EBIT: As of FY2026 Q1, the actual value is USD -2.543 M.

#### Financial Highlights

**Total Revenue**Xtant Medical Holdings, Inc. generated total revenue of $20.9 million for the first quarter of 2026, a decrease from $32.9 million for the first quarter of 2025. This decline is primarily attributed to the sale of assets and businesses to Companion Spine in December 2025, as well as non-recurring license revenue from 2025. Product revenue was $20,884 thousand for Q1 2026, down from $29,284 thousand for Q1 2025. License revenue was $0 for Q1 2026, compared to $3,620 thousand for Q1 2025.

**Gross Margin**Gross margin for the first quarter of 2026 was 57.3%, down from 61.5% for the same period in 2025.

**Operating Expenses**Total operating expenses for the first quarter of 2026 were $14.9 million, a reduction from $19.2 million for the first quarter of 2025.

**Net Income/Loss**The company reported a net loss of - $3.1 million for the first quarter of 2026, compared to a net income of $58,000 for the first quarter of 2025.

**Non-GAAP Adjusted EBITDA**Non-GAAP adjusted EBITDA loss for the first quarter of 2026 totaled - $1.6 million, a decrease from a positive adjusted EBITDA of $3.0 million for the same period in 2025.

#### Balance Sheet & Indebtedness

**Total Indebtedness**Xtant Medical Holdings, Inc. reduced its total indebtedness by $13.3 million in the first quarter of 2026. Total indebtedness was $12.2 million as of March 31, 2026, down from $25.4 million as of December 31, 2025.

**Cash and Cash Equivalents**As of March 31, 2026, the company had $12.2 million in cash and cash equivalents, compared to $17.3 million as of December 31, 2025.

**Revolving Credit Facility**Availability under its revolving credit facility increased to $11.8 million as of March 31, 2026, from $3.8 million as of December 31, 2025.

#### Cash Flow from Operating Activities

**Net Cash Used in Operating Activities**Net cash used in operating activities for the three months ended March 31, 2026, was - $2,114 thousand, compared to net cash provided by operating activities of $1,278 thousand for the same period in 2025.

#### Operational Highlights

Xtant Medical Holdings, Inc. announced an exclusive U.S. distribution agreement with Dilon Technologies for its HEMOBLAST® Bellows product, and hired Dilon’s approximately 20-person U.S. sales team. The company launched Trivium™ Shaped, an extension of its demineralized bone matrix allograft product line. Xtant Medical Holdings, Inc. received the final $10.7 million due from Companion Spine in March, completing the previously announced sale of its Coflex®/CoFix assets and international hardware business for a total cash purchase price of $21.4 million.

#### Outlook / Guidance

Xtant Medical Holdings, Inc. increased its full-year 2026 revenue guidance to a range of $101 million to $105 million, up from the previous range of $95 million to $99 million. This revised guidance reflects the anticipated incremental revenue contribution from Dilon’s HEMOBLAST® Bellows product following the exclusive license agreement. The company expects to drive topline growth and margin expansion through the integration of Dilon’s sales force and recent product launches.

### Related Stocks

- [XTNT.US](https://longbridge.com/en/quote/XTNT.US.md)

## Related News & Research

- [Xtant Medical Reports First Quarter 2026 Financial Results | XTNT Stock News](https://longbridge.com/en/news/286247087.md)
- [Xtant Medical Updates Q1 Results and Raises 2026 Guidance](https://longbridge.com/en/news/286254004.md)
- [How Investors May Respond To American Healthcare REIT (AHR) Cutting 2026 Profit Outlook After Q1 Results](https://longbridge.com/en/news/286866277.md)
- [Xtant Medical Q1 revenue falls less than expected, outlook raised](https://longbridge.com/en/news/286248707.md)
- [Lipocine to Present at A.G.P. Virtual Healthcare Showcase May 20](https://longbridge.com/en/news/286776630.md)